Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the 37th Annual Roth Conference
NEW YORK, March 17, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
TMCnet2d
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Latest death notices across Wales as families remember loved ones
Announcing the passing of a loved one in local news media is a long standing tradition and we are proud of the trust placed ...
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Frontiers15d
Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells
In some cases, we attempted to enhance the staining by particular mAbs to better distinguish leukocyte subsets, as was the case for the anti-CD94 mAb HP-3D9. This was done by staining dog cells ...
Business Insider20d
Why Paul Singer, the octogenarian founder of $72 billion Elliott Management, does not have fun at work
Paul Singer, the founder of the $72 billion hedge fund Elliott Management, has made a fortune out of being stressed. The billionaire, who launched his firm in 1977 and has famously lost money in ...
9&10 News22d
2025 MAB Awards announced - 9&10 among multiple-award winners
The 2025 MAB Awards, presented by the Michigan Association of Broadcasters, were announced Monday, Feb. 24. Awards were handed out in the following categories: Commercial & Network Television ...
infectiousdiseaseadvisor.com22d
COVID Antiviral, mAb Treatments Reduce Mortality and Hospitalization Rates
1 subvariants and nirmatrelvir/ritonavir was effective against Omicron BA.2/BA.4/BA.5 subvariants. Certain antiviral drugs and monoclonal antibody (mAb) therapies continue to lower mortality risk and ...
The New Zealand Herald23d
Super Rugby Pacific: Back to the future as new life breathed into competition – Gregor Paul
Super Rugby is forever trying to brand each week with a gimmicky name, but after two rounds of action, a retro theme has organically developed in 2025, and it’s one that is carrying considerably ...